You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEletriptan
Accession NumberDB00216  (APRD00945)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionEletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches. [Wikipedia]
Structure
Thumb
Synonyms
Eletriptanum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Gd-eletriptanTablet20 mgOralGenmed A Division Of Pfizer Canada Inc2012-10-11Not applicableCanada
Gd-eletriptanTablet40 mgOralGenmed A Division Of Pfizer Canada Inc2012-10-11Not applicableCanada
PMS-eletriptanTablet20 mgOralPharmascience Inc2014-11-26Not applicableCanada
PMS-eletriptanTablet40 mgOralPharmascience Inc2014-11-26Not applicableCanada
RelpaxTablet40 mgOralPfizer Canada Inc2004-10-13Not applicableCanada
RelpaxTablet, film coated20 mg/1OralRoerig2002-12-26Not applicableUs
RelpaxTablet, film coated40 mg/1OralPhysicians Total Care, Inc.2007-11-19Not applicableUs
RelpaxTablet, film coated40 mg/1OralRoerig2002-12-26Not applicableUs
RelpaxTablet, film coated40 mg/1OralU.S. Pharmaceuticals2002-12-26Not applicableUs
RelpaxTablet, film coated40 mg/1OralSTAT Rx USA LLC2002-12-26Not applicableUs
RelpaxTablet20 mgOralPfizer Canada Inc2004-10-13Not applicableCanada
RelpaxTablet, film coated40 mg/1OralRebel Distributors Corp2002-12-26Not applicableUs
Teva-eletriptanTablet40 mgOralTeva Canada Limited2013-12-20Not applicableCanada
Teva-eletriptanTablet20 mgOralTeva Canada Limited2013-12-20Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-eletriptanTablet20 mgOralApotex Inc2013-09-12Not applicableCanada
Apo-eletriptanTablet40 mgOralApotex Inc2013-09-12Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Eletriptan hydrobromide
ThumbNot applicableDBSALT000884
Categories
UNII22QOO9B8KI
CAS number143322-58-1
WeightAverage: 382.519
Monoisotopic: 382.171498776
Chemical FormulaC22H26N2O2S
InChI KeyPWVXXGRKLHYWKM-LJQANCHMSA-N
InChI
InChI=1S/C22H26N2O2S/c1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20/h2-4,7-10,14,16,19,23H,5-6,11-13,15H2,1H3/t19-/m1/s1
IUPAC Name
5-[2-(benzenesulfonyl)ethyl]-3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-1H-indole
SMILES
CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2
Pharmacology
IndicationFor the acute treatment of migraine with or without aura in adults.
Structured Indications
PharmacodynamicsEletriptan is a selective 5-hydroxytryptamine 1B/1D receptor agonist. In the anesthetized dog, eletriptan has been shown to reduce carotid arterial blood flow, with only a small increase in arterial blood pressure at high doses. While the effect on blood flow was selective for the carotid arterial bed, decreases in coronary artery diameter were observed. Eletriptan has also been shown to inhibit trigeminal nerve activity in the rat.
Mechanism of actionEletriptan binds with high affinity to 5-HT1B, 5-HT1D and 5-HT1F receptors, has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors, and little or no affinity for 5-HT2A, 5-HT2C, 5-HT3, 5-HT4, 5-HT5A and 5-HT6 receptors. Eletriptan has no significant affinity or pharmacological activity at adrenergic alpha1, alpha2, or beta; dopaminergic D1 or D2; muscarinic; or opioid receptors. Two theories have been proposed to explain the efficacy of 5-HT receptor agonists in migraine. One theory suggests that activation of 5-HT1 receptors located on intracranial blood vessels, including those on the arteriovenous anastomoses, leads to vasoconstriction, which is correlated with the relief of migraine headache. The other hypothesis suggests that activation of 5-HT1 receptors on sensory nerve endings in the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release.
TargetKindPharmacological actionActionsOrganismUniProt ID
5-hydroxytryptamine receptor 1DProteinyes
agonist
HumanP28221 details
5-hydroxytryptamine receptor 1BProteinyes
agonist
HumanP28222 details
5-hydroxytryptamine receptor 1FProteinyes
agonist
HumanP30939 details
5-hydroxytryptamine receptor 1AProteinunknown
agonist
HumanP08908 details
5-hydroxytryptamine receptor 1EProteinunknown
agonist
HumanP28566 details
5-hydroxytryptamine receptor 2BProteinunknown
agonist
HumanP41595 details
5-hydroxytryptamine receptor 7Proteinunknown
agonist
HumanP34969 details
Related Articles
AbsorptionWell absorbed after oral administration with a mean absolute bioavailability of approximately 50%.
Volume of distribution
  • 138 L
Protein bindingPlasma protein binding is moderate and approximately 85%.
Metabolism

In vitro studies indicate that eletriptan is primarily metabolized by cytochrome P-450 enzyme CYP3A4. The N-demethylated metabolite of eletriptan is the only known active metabolite.

SubstrateEnzymesProduct
Eletriptan
N-DesmethyleletriptanDetails
Eletriptan
Eletriptan N-oxideDetails
Route of eliminationNot Available
Half lifeThe terminal elimination half-life of eletriptan is approximately 4 hours.
Clearance
  • Renal cl=3.9 L/h
ToxicityBased on the pharmacology of the 5-HT1B/1D agonists, hypertension or other more serious cardiovascular symptoms could occur on overdose.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3
Gene symbol: GNB3
UniProt: P16520
rs5443 Not AvailableT AlleleBetter response to drug treatment17361120
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe metabolism of Eletriptan can be decreased when combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AbirateroneThe serum concentration of Eletriptan can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Eletriptan can be increased when it is combined with Acetaminophen.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Acetophenazine.Approved
AfatinibThe serum concentration of Eletriptan can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Eletriptan can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Eletriptan can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Eletriptan can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Eletriptan can be increased when it is combined with Alfentanil.Approved, Illicit
AlmotriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Almotriptan.Approved, Investigational
AmantadineThe serum concentration of Eletriptan can be increased when it is combined with Amantadine.Approved
Aminohippuric acidThe serum concentration of Eletriptan can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Eletriptan can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Eletriptan is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Eletriptan can be increased when it is combined with Amlodipine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Eletriptan is combined with Amperozide.Experimental
AmprenavirThe serum concentration of Eletriptan can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Eletriptan can be increased when it is combined with Amsacrine.Approved
AprepitantThe serum concentration of Eletriptan can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Eletriptan.Approved, Investigational
ArmodafinilThe metabolism of Eletriptan can be decreased when combined with Armodafinil.Approved, Investigational
ArtemetherThe metabolism of Eletriptan can be decreased when combined with Artemether.Approved
AsenapineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Asenapine.Approved
AstemizoleThe serum concentration of Eletriptan can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Eletriptan can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Eletriptan can be increased when it is combined with Atenolol.Approved
AtomoxetineThe serum concentration of Eletriptan can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Eletriptan can be increased when it is combined with Atorvastatin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Azaperone.Vet Approved
AzelastineThe serum concentration of Eletriptan can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Eletriptan can be increased when it is combined with Azithromycin.Approved
BenmoxinThe metabolism of Eletriptan can be decreased when combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Eletriptan is combined with Benperidol.Investigational
BenzocaineThe serum concentration of Eletriptan can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Eletriptan can be increased when it is combined with Bepridil.Approved, Withdrawn
BetaxololThe metabolism of Eletriptan can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Eletriptan can be decreased when it is combined with Bexarotene.Approved, Investigational
BifeprunoxThe risk or severity of adverse effects can be increased when Eletriptan is combined with Bifeprunox.Investigational
BiperidenThe serum concentration of Eletriptan can be increased when it is combined with Biperiden.Approved
BoceprevirThe serum concentration of Eletriptan can be increased when it is combined with Boceprevir.Approved
BortezomibThe serum concentration of Eletriptan can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Eletriptan can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Eletriptan can be increased when it is combined with Bosutinib.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Eletriptan is combined with Brexpiprazole.Approved
BromocriptineBromocriptine may increase the vasoconstricting activities of Eletriptan.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Eletriptan is combined with Bromperidol.Investigational
BuprenorphineThe serum concentration of Eletriptan can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Eletriptan can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Eletriptan is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Eletriptan can be increased when it is combined with Cabazitaxel.Approved
CabergolineCabergoline may increase the vasoconstricting activities of Eletriptan.Approved
CaffeineThe serum concentration of Eletriptan can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Eletriptan can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Eletriptan can be increased when it is combined with Candesartan.Approved
CapecitabineThe metabolism of Eletriptan can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Eletriptan can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Eletriptan can be increased when combined with Carbamazepine.Approved, Investigational
CariprazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Cariprazine.Approved
CaroxazoneThe metabolism of Eletriptan can be decreased when combined with Caroxazone.Withdrawn
CarvedilolThe serum concentration of Eletriptan can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Eletriptan can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Eletriptan can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Eletriptan can be increased when it is combined with Ceritinib.Approved
ChloramphenicolThe metabolism of Eletriptan can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe serum concentration of Eletriptan can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Eletriptan can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Eletriptan can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Eletriptan can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholecalciferolThe metabolism of Eletriptan can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Eletriptan can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Eletriptan can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Eletriptan can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Eletriptan can be decreased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Eletriptan can be decreased when combined with Cinacalcet.Approved
CiprofloxacinThe serum concentration of Eletriptan can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Eletriptan.Approved
ClarithromycinThe serum concentration of Eletriptan can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Eletriptan can be increased when it is combined with Clemastine.Approved
ClobazamThe metabolism of Eletriptan can be decreased when combined with Clobazam.Approved, Illicit
ClofazimineThe serum concentration of Eletriptan can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Clomipramine.Approved, Vet Approved
ClotrimazoleThe serum concentration of Eletriptan can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Eletriptan can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Eletriptan can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Eletriptan can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Eletriptan can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Eletriptan can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Eletriptan can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe serum concentration of Eletriptan can be increased when it is combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Cyamemazine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Cyclobenzaprine.Approved
CyclophosphamideThe serum concentration of Eletriptan can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Eletriptan can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Eletriptan can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Eletriptan can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Eletriptan can be increased when it is combined with Dactinomycin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Eletriptan is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Eletriptan.Investigational
DarifenacinThe metabolism of Eletriptan can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Eletriptan can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Eletriptan can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Eletriptan can be decreased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Eletriptan can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Eletriptan can be increased when it is combined with Delavirdine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Desipramine.Approved
DesloratadineThe serum concentration of Eletriptan can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Desvenlafaxine.Approved
DexamethasoneThe serum concentration of Eletriptan can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Eletriptan can be increased when it is combined with Diclofenac.Approved, Vet Approved
DigoxinThe serum concentration of Eletriptan can be decreased when it is combined with Digoxin.Approved
DihydroergotamineThe serum concentration of Eletriptan can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Eletriptan can be increased when it is combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Eletriptan can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe serum concentration of Eletriptan can be increased when it is combined with Dipyridamole.Approved
DolasetronDolasetron may increase the serotonergic activities of Eletriptan.Approved
DoxazosinThe serum concentration of Eletriptan can be increased when it is combined with Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Eletriptan is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Eletriptan can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe serum concentration of Eletriptan can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Eletriptan can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Eletriptan can be increased when it is combined with Dronedarone.Approved
DroperidolThe risk or severity of adverse effects can be increased when Eletriptan is combined with Droperidol.Approved, Vet Approved
DroxidopaEletriptan may increase the hypertensive activities of Droxidopa.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Duloxetine.Approved
EcopipamThe risk or severity of adverse effects can be increased when Eletriptan is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Eletriptan can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Eletriptan can be increased when it is combined with Elbasvir.Approved
EliglustatThe metabolism of Eletriptan can be decreased when combined with Eliglustat.Approved
EnalaprilThe serum concentration of Eletriptan can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Eletriptan can be decreased when it is combined with Enzalutamide.Approved
Ergoloid mesylateErgoloid mesylate may increase the vasoconstricting activities of Eletriptan.Approved
ErgonovineErgonovine may increase the vasoconstricting activities of Eletriptan.Approved
ErgotamineErgotamine may increase the vasoconstricting activities of Eletriptan.Approved
ErythromycinThe serum concentration of Eletriptan can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Eletriptan is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Eletriptan can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Eletriptan can be decreased when combined with Esomeprazole.Approved, Investigational
EstramustineThe serum concentration of Eletriptan can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Eletriptan can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Eletriptan can be decreased when it is combined with Estrone.Approved
EtoposideThe serum concentration of Eletriptan can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Eletriptan can be decreased when it is combined with Etravirine.Approved
FelodipineThe serum concentration of Eletriptan can be increased when it is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Eletriptan is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Eletriptan can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Eletriptan can be increased when it is combined with Fidaxomicin.Approved
FloxuridineThe metabolism of Eletriptan can be decreased when combined with Floxuridine.Approved
FluconazoleThe serum concentration of Eletriptan can be increased when it is combined with Fluconazole.Approved
FluorouracilThe metabolism of Eletriptan can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Eletriptan can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Eletriptan can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Eletriptan can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Eletriptan can be increased when it is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Fluspirilene.Approved
FluvastatinThe metabolism of Eletriptan can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe serum concentration of Eletriptan can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Eletriptan can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Eletriptan can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Eletriptan can be increased when combined with Fosphenytoin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Frovatriptan.Approved, Investigational
FurazolidoneThe metabolism of Eletriptan can be decreased when combined with Furazolidone.Approved, Vet Approved
Fusidic AcidThe serum concentration of Eletriptan can be increased when it is combined with Fusidic Acid.Approved
GefitinibThe serum concentration of Eletriptan can be increased when it is combined with Gefitinib.Approved, Investigational
GemfibrozilThe metabolism of Eletriptan can be decreased when combined with Gemfibrozil.Approved
GenisteinThe serum concentration of Eletriptan can be increased when it is combined with Genistein.Investigational
GlyburideThe serum concentration of Eletriptan can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Eletriptan can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Eletriptan can be increased when it is combined with Gramicidin D.Approved
GranisetronGranisetron may increase the serotonergic activities of Eletriptan.Approved, Investigational
GrepafloxacinThe serum concentration of Eletriptan can be increased when it is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Eletriptan can be increased when it is combined with Haloperidol.Approved
HydracarbazineThe metabolism of Eletriptan can be decreased when combined with Hydracarbazine.Approved
HydrocortisoneThe serum concentration of Eletriptan can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
IdelalisibThe serum concentration of Eletriptan can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Iloperidone.Approved
ImatinibThe serum concentration of Eletriptan can be increased when it is combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Imipramine.Approved
IndinavirThe serum concentration of Eletriptan can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Eletriptan can be increased when it is combined with Indomethacin.Approved, Investigational
IproclozideThe metabolism of Eletriptan can be decreased when combined with Iproclozide.Withdrawn
IproniazidThe metabolism of Eletriptan can be decreased when combined with Iproniazid.Withdrawn
IrbesartanThe metabolism of Eletriptan can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe serum concentration of Eletriptan can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe metabolism of Eletriptan can be decreased when combined with Isocarboxazid.Approved
IsoniazidThe metabolism of Eletriptan can be decreased when combined with Isoniazid.Approved
IsradipineThe serum concentration of Eletriptan can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Eletriptan can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Eletriptan can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Eletriptan can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Eletriptan can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe serum concentration of Eletriptan can be increased when it is combined with Ketoconazole.Approved, Investigational
LansoprazoleThe serum concentration of Eletriptan can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Eletriptan can be increased when it is combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Eletriptan can be decreased when combined with Leflunomide.Approved, Investigational
LevofloxacinThe serum concentration of Eletriptan can be increased when it is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Eletriptan is combined with Levomilnacipran.Approved
LevothyroxineThe serum concentration of Eletriptan can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Eletriptan can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Eletriptan is combined with Linezolid.Approved, Investigational
LiothyronineThe serum concentration of Eletriptan can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Eletriptan can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Eletriptan can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Eletriptan is combined with Lithium.Approved
LomitapideThe serum concentration of Eletriptan can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Eletriptan can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Eletriptan can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Eletriptan can be increased when it is combined with Loratadine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Eletriptan is combined with Lorcaserin.Approved
LosartanThe serum concentration of Eletriptan can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Eletriptan can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Loxapine.Approved
LuliconazoleThe serum concentration of Eletriptan can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Eletriptan can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Eletriptan can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Lurasidone.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Maprotiline.Approved
MebanazineThe metabolism of Eletriptan can be decreased when combined with Mebanazine.Withdrawn
MebendazoleThe serum concentration of Eletriptan can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Eletriptan can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Eletriptan can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Melperone.Approved
MeprobamateThe serum concentration of Eletriptan can be increased when it is combined with Meprobamate.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Mesoridazine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Methadone.Approved
MethotrimeprazineThe metabolism of Eletriptan can be decreased when combined with Methotrimeprazine.Approved
Methylene blueThe metabolism of Eletriptan can be decreased when combined with Methylene blue.Investigational
MetoclopramideThe risk or severity of adverse effects can be increased when Eletriptan is combined with Metoclopramide.Approved, Investigational
MetoprololThe serum concentration of Eletriptan can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Eletriptan can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Eletriptan can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Eletriptan can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Eletriptan can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Eletriptan is combined with Milnacipran.Approved
MinaprineThe metabolism of Eletriptan can be decreased when combined with Minaprine.Approved
MirabegronThe metabolism of Eletriptan can be decreased when combined with Mirabegron.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Mirtazapine.Approved
MitomycinThe serum concentration of Eletriptan can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Eletriptan can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Eletriptan can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideThe metabolism of Eletriptan can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Eletriptan can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Molindone.Approved
MorphineThe serum concentration of Eletriptan can be increased when it is combined with Morphine.Approved, Investigational
NafcillinThe serum concentration of Eletriptan can be decreased when it is combined with Nafcillin.Approved
NaltrexoneThe serum concentration of Eletriptan can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Naratriptan.Approved, Investigational
NaringeninThe serum concentration of Eletriptan can be increased when it is combined with Naringenin.Experimental
NefazodoneThe serum concentration of Eletriptan can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Eletriptan can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Eletriptan can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Eletriptan can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Eletriptan can be increased when it is combined with Nevirapine.Approved
NialamideThe metabolism of Eletriptan can be decreased when combined with Nialamide.Withdrawn
NicardipineThe metabolism of Eletriptan can be decreased when combined with Nicardipine.Approved
NifedipineThe serum concentration of Eletriptan can be decreased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Eletriptan can be increased when it is combined with Nilotinib.Approved, Investigational
NisoldipineThe serum concentration of Eletriptan can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Eletriptan can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Eletriptan can be increased when it is combined with Nitrendipine.Approved
NorethisteroneThe serum concentration of Eletriptan can be decreased when it is combined with Norethisterone.Approved
NortriptylineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Nortriptyline.Approved
OctamoxinThe metabolism of Eletriptan can be decreased when combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Eletriptan can be increased when it is combined with Olaparib.Approved
OmeprazoleThe serum concentration of Eletriptan can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the serotonergic activities of Eletriptan.Approved
OsanetantThe risk or severity of adverse effects can be increased when Eletriptan is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Eletriptan can be increased when it is combined with Osimertinib.Approved
P-NitrophenolThe serum concentration of Eletriptan can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Eletriptan can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Eletriptan can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Paliperidone.Approved
Palmitic AcidThe serum concentration of Eletriptan can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronPalonosetron may increase the serotonergic activities of Eletriptan.Approved, Investigational
PanobinostatThe serum concentration of Eletriptan can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Eletriptan can be increased when it is combined with Pantoprazole.Approved
PargylineThe metabolism of Eletriptan can be decreased when combined with Pargyline.Approved
ParoxetineThe metabolism of Eletriptan can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Eletriptan can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe metabolism of Eletriptan can be increased when combined with Pentobarbital.Approved, Vet Approved
PerazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Perazine.Investigational
PerindoprilThe serum concentration of Eletriptan can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Eletriptan is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Pethidine.Approved
PhenelzineThe metabolism of Eletriptan can be decreased when combined with Phenelzine.Approved
PheniprazineThe metabolism of Eletriptan can be decreased when combined with Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Eletriptan can be increased when combined with Phenobarbital.Approved
PhenoxypropazineThe metabolism of Eletriptan can be decreased when combined with Phenoxypropazine.Withdrawn
PhenytoinThe metabolism of Eletriptan can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe serum concentration of Eletriptan can be increased when it is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Pipotiazine.Approved
PirlindoleThe metabolism of Eletriptan can be decreased when combined with Pirlindole.Approved
PivhydrazineThe metabolism of Eletriptan can be decreased when combined with Pivhydrazine.Withdrawn
Platelet Activating FactorThe serum concentration of Eletriptan can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Eletriptan can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Eletriptan can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Eletriptan can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Eletriptan can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Eletriptan can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe metabolism of Eletriptan can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Eletriptan can be increased when it is combined with Probenecid.Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Procarbazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Prochlorperazine.Approved, Vet Approved
ProgesteroneThe serum concentration of Eletriptan can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe metabolism of Eletriptan can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Promethazine.Approved
PropafenoneThe serum concentration of Eletriptan can be increased when it is combined with Propafenone.Approved
PropericiazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Propericiazine.Approved
PropranololThe serum concentration of Eletriptan can be increased when it is combined with Propranolol.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Eletriptan is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Protriptyline.Approved
PyrimethamineThe metabolism of Eletriptan can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuercetinThe serum concentration of Eletriptan can be increased when it is combined with Quercetin.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Eletriptan can be increased when it is combined with Quinacrine.Approved
QuinidineThe metabolism of Eletriptan can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Eletriptan can be increased when it is combined with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Eletriptan is combined with Raclopride.Investigational
RanitidineThe serum concentration of Eletriptan can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Eletriptan can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe metabolism of Eletriptan can be decreased when combined with Rasagiline.Approved
ReboxetineThe serum concentration of Eletriptan can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Eletriptan can be increased when it is combined with Regorafenib.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Eletriptan is combined with Remoxipride.Approved, Withdrawn
ReserpineThe serum concentration of Eletriptan can be decreased when it is combined with Reserpine.Approved
RifabutinThe metabolism of Eletriptan can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Eletriptan can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Eletriptan can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Eletriptan can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Eletriptan is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Eletriptan can be increased when it is combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Rizatriptan.Approved
RolapitantThe serum concentration of Eletriptan can be increased when it is combined with Rolapitant.Approved
RopiniroleThe metabolism of Eletriptan can be decreased when combined with Ropinirole.Approved, Investigational
SafrazineThe metabolism of Eletriptan can be decreased when combined with Safrazine.Withdrawn
SaquinavirThe serum concentration of Eletriptan can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Eletriptan.Approved
ScopolamineThe serum concentration of Eletriptan can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Eletriptan can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Eletriptan can be decreased when combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Eletriptan is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Sertraline.Approved
SildenafilThe serum concentration of Eletriptan can be increased when it is combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Eletriptan can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Eletriptan can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Eletriptan can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Eletriptan can be decreased when it is combined with Sirolimus.Approved, Investigational
SorafenibThe serum concentration of Eletriptan can be increased when it is combined with Sorafenib.Approved, Investigational
SpironolactoneThe serum concentration of Eletriptan can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Eletriptan can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Eletriptan can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Eletriptan can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Eletriptan can be decreased when it is combined with Streptozocin.Approved
SulfadiazineThe metabolism of Eletriptan can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Eletriptan can be decreased when combined with Sulfamethoxazole.Approved
SulfinpyrazoneThe serum concentration of Eletriptan can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe serum concentration of Eletriptan can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Eletriptan is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Eletriptan can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Eletriptan can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Eletriptan can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Eletriptan can be decreased when it is combined with Tamoxifen.Approved
TapentadolThe risk or severity of adverse effects can be increased when Eletriptan is combined with Tapentadol.Approved
Taurocholic AcidThe serum concentration of Eletriptan can be increased when it is combined with Taurocholic Acid.Experimental
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Eletriptan.Approved
TelaprevirThe serum concentration of Eletriptan can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Eletriptan can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Eletriptan can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Eletriptan can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Eletriptan can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Eletriptan can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Eletriptan can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Eletriptan can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Eletriptan can be increased when it is combined with Testosterone.Approved, Investigational
ThioproperazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Thioproperazine.Approved
ThioridazineThe metabolism of Eletriptan can be decreased when combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Thiothixene.Approved
TiaprideThe risk or severity of adverse effects can be increased when Eletriptan is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Eletriptan can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Eletriptan can be increased when it is combined with Ticlopidine.Approved
TipranavirThe metabolism of Eletriptan can be decreased when combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Eletriptan can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Eletriptan can be decreased when combined with Tolbutamide.Approved
ToloxatoneThe metabolism of Eletriptan can be decreased when combined with Toloxatone.Approved
TolvaptanThe serum concentration of Eletriptan can be increased when it is combined with Tolvaptan.Approved
TopiramateThe metabolism of Eletriptan can be decreased when combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Eletriptan.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe metabolism of Eletriptan can be decreased when combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Eletriptan can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Eletriptan can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Eletriptan can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Eletriptan can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Eletriptan can be increased when it is combined with Troleandomycin.Approved
TropisetronTropisetron may increase the serotonergic activities of Eletriptan.Investigational
Valproic AcidThe metabolism of Eletriptan can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Eletriptan can be decreased when combined with Valsartan.Approved, Investigational
VenlafaxineThe serum concentration of Eletriptan can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Eletriptan can be increased when it is combined with Verapamil.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Vilazodone.Approved
VinblastineThe serum concentration of Eletriptan can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Eletriptan can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Eletriptan can be increased when it is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe serum concentration of Eletriptan can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Vortioxetine.Approved
ZafirlukastThe metabolism of Eletriptan can be decreased when combined with Zafirlukast.Approved, Investigational
ZimelidineThe serum concentration of Eletriptan can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Eletriptan can be increased when it is combined with Ziprasidone.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Zolmitriptan.Approved, Investigational
ZotepineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Eletriptan is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Exposure to the product (area below curve) and maximum concentrations are increased when product is taken with a high-fat meal.
References
Synthesis Reference

Ronald Ogilvie, “Process for the preparation of eletriptan.” U.S. Patent US20050059828, issued March 17, 2005.

US20050059828
General ReferencesNot Available
External Links
ATC CodesN02CC06
AHFS Codes
  • 28:32.28
PDB EntriesNot Available
FDA labelDownload (148 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9872
Blood Brain Barrier+0.9774
Caco-2 permeable-0.628
P-glycoprotein substrateSubstrate0.6308
P-glycoprotein inhibitor INon-inhibitor0.8046
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterInhibitor0.7
CYP450 2C9 substrateNon-substrate0.6591
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.643
CYP450 1A2 substrateNon-inhibitor0.7021
CYP450 2C9 inhibitorNon-inhibitor0.8103
CYP450 2D6 inhibitorNon-inhibitor0.7615
CYP450 2C19 inhibitorNon-inhibitor0.7519
CYP450 3A4 inhibitorNon-inhibitor0.6355
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6986
Ames testNon AMES toxic0.5945
CarcinogenicityNon-carcinogens0.8556
BiodegradationNot ready biodegradable0.9883
Rat acute toxicity2.5492 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6436
hERG inhibition (predictor II)Inhibitor0.7581
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pfizer ireland pharmaceuticals
Packagers
Dosage forms
FormRouteStrength
TabletOral20 mg
TabletOral40 mg
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral40 mg/1
Prices
Unit descriptionCostUnit
Relpax 6 20 mg tablet Box156.05USD box
Relpax 6 40 mg tablet Box156.05USD box
Relpax 20 mg tablet25.01USD tablet
Relpax 40 mg tablet25.01USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2198599 No2000-06-062015-05-17Canada
CA2352392 No2006-01-242019-11-01Canada
US5545644 No1996-12-262016-12-26Us
US6110940 No1997-08-292017-08-29Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityReadily soluble as hydrobromide formulationNot Available
logP3.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00118 mg/mLALOGPS
logP3.84ALOGPS
logP3.77ChemAxon
logS-5.5ALOGPS
pKa (Strongest Acidic)17.11ChemAxon
pKa (Strongest Basic)8.37ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area53.17 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity110.94 m3·mol-1ChemAxon
Polarizability42.99 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as indoles. These are compounds containing an indole moiety, which consists of pyrrole ring fused to benzene to form 2,3-benzopyrrole.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIndoles and derivatives
Sub ClassIndoles
Direct ParentIndoles
Alternative Parents
Substituents
  • Indole
  • Aralkylamine
  • Benzenoid
  • N-alkylpyrrolidine
  • Substituted pyrrole
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Sulfonyl
  • Sulfone
  • Pyrrolidine
  • Pyrrole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R: Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68. [PubMed:10193663 ]
  3. Wackenfors A, Jarvius M, Ingemansson R, Edvinsson L, Malmsjo M: Triptans induce vasoconstriction of human arteries and veins from the thoracic wall. J Cardiovasc Pharmacol. 2005 May;45(5):476-84. [PubMed:15821444 ]
  4. Johnson DE, Rollema H, Schmidt AW, McHarg AD: Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain. Eur J Pharmacol. 2001 Aug 17;425(3):203-10. [PubMed:11513839 ]
  5. Strijbos PJ, Parsons AA, Fugelli A: Eletriptan Pfizer. Curr Opin Investig Drugs. 2002 Sep;3(9):1359-68. [PubMed:12498013 ]
  6. Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87. [PubMed:11152011 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R: Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68. [PubMed:10193663 ]
  2. van den Broek RW, MaassenVanDenBrink A, de Vries R, Bogers AJ, Stegmann AP, Avezaat CJ, Saxena PR: Pharmacological analysis of contractile effects of eletriptan and sumatriptan on human isolated blood vessels. Eur J Pharmacol. 2000 Oct 27;407(1-2):165-73. [PubMed:11050304 ]
  3. Knyihar-Csillik E, Tajti J, Csillik AE, Chadaide Z, Mihaly A, Vecsei L: Effects of eletriptan on the peptidergic innervation of the cerebral dura mater and trigeminal ganglion, and on the expression of c-fos and c-jun in the trigeminal complex of the rat in an experimental migraine model. Eur J Neurosci. 2000 Nov;12(11):3991-4002. [PubMed:11069595 ]
  4. Johnson DE, Rollema H, Schmidt AW, McHarg AD: Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain. Eur J Pharmacol. 2001 Aug 17;425(3):203-10. [PubMed:11513839 ]
  5. Lambert GA, Boers PM, Hoskin KL, Donaldson C, Zagami AS: Suppression by eletriptan of the activation of trigeminovascular sensory neurons by glyceryl trinitrate. Brain Res. 2002 Oct 25;953(1-2):181-8. [PubMed:12384251 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
Gene Name:
HTR1F
Uniprot ID:
P30939
Molecular Weight:
41708.505 Da
References
  1. Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R: Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68. [PubMed:10193663 ]
  2. Bhalla P, Sharma HS, Wurch T, Pauwels PJ, Saxena PR: Molecular cloning and expression of the porcine trigeminal ganglion cDNA encoding a 5-ht(1F) receptor. Eur J Pharmacol. 2002 Feb 1;436(1-2):23-33. [PubMed:11834243 ]
  3. Jahnichen S, Radtke OA, Pertz HH: Involvement of 5-HT1B receptors in triptan-induced contractile responses in guinea-pig isolated iliac artery. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):54-63. Epub 2004 Jun 8. [PubMed:15185063 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Johnson DE, Rollema H, Schmidt AW, McHarg AD: Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain. Eur J Pharmacol. 2001 Aug 17;425(3):203-10. [PubMed:11513839 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
Gene Name:
HTR1E
Uniprot ID:
P28566
Molecular Weight:
41681.57 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins ...
Gene Name:
HTR2B
Uniprot ID:
P41595
Molecular Weight:
54297.41 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Evans DC, O'Connor D, Lake BG, Evers R, Allen C, Hargreaves R: Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos. 2003 Jul;31(7):861-9. [PubMed:12814962 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 02:41